Safety & tolerability of bedaquiline & delamanid along with background regimen for treatment of Paediatric DRTB(RR)/MDR/Pre XDR/XDR TB) in children aged 6-18 years | India Science, Technology & Innovation - ISTI Portal

×

Acces sibility Controls

Safety & tolerability of bedaquiline & delamanid along with background regimen for treatment of Paediatric DRTB(RR)/MDR/Pre XDR/XDR TB) in children aged 6-18 years

Implementing Organization

National Institute of Tuberculosis & Respiratory Diseases, Delhi

Principal Investigator

Prof. S. Sharma

National Institute of Tuberculosis & Respiratory Diseases, Delhi

Source

Source

Extramural R&D Projects listed in NSTMIS database 2019-20

Related Research

Quick Information

Area of Research

Medical Sciences

Focus Area

Ad-hoc, ADHOC

Start Year

2019

End Year

2022

Sanction Amount

₹ 29.07 L

Status

Completed

Output

No. of Research Paper

00

Technologies (If Any)

00

No. of PhD Produced

00

No. of Patents

Filed : 00

Grant : 00

Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.

Latest Updates

Loading…